PTYLTD
    • Free Reports
    • Videos
  • Pricing
  • About us
  • Contact us
  • Login | Sign up
PTYLTD

Free Reports

Videos

Pricing

About us

Contact us

  • Home
  • Insights into ASX Stocks
  • By Sector

4DMedical (ASX: 4DX)

Is 4DMedical (ASX: 4DX) the Next High-Growth MedTech Breakout or a Funding Risk?

Apr 15, 2026
Proactive Equities Team

4DMedical Limited is an Australian medtech company developing lung imaging software that turns standard scans into functional insights. It has strong growth potential through scalable products like CT:VQ, but remains speculative due to ongoing cash burn, reliance on adoption, and funding risk.

Cochlear (ASX: COH)

Why Cochlear's (ASX: COH) share price keeps crashing, and where can it find a bottom?

Apr 24, 2026
Proactive Equities Team

Cochlear’s share price slump reflects profit downgrades, slowing growth, weak global demand, and macro pressures. The stock is down sharply, but a lasting bottom likely depends on stabilising earnings and clearer signs of demand recovery.

Lumos Diagnostics (ASX: LDX)

Lumos Diagnostics (ASX: LDX): Shares Keep Sliding Despite Last Year’s Rally

May 18, 2026
Proactive Equities Team

Lumos Diagnostics shares have dropped sharply after last year’s rally, with weak technical signals and dilution concerns weighing on sentiment. Despite long-term optimism around FebriDx and US commercialisation, investors remain cautious due to slow revenue growth and ongoing funding pressures.

PolyNovo (ASX: PNV)

PolyNovo (ASX: PNV): Our Bottoming Thesis Confirmed by a Breakout Move

May 21, 2026
Proactive Equities Team

PolyNovo (ASX: PNV) is an advanced wound care company whose NovoSorb platform drives strong U.S.-led growth. After the March weakness from leadership changes, improving revenues and a technical breakout above the trend signal a potential bottom and renewed bullish momentum.

EBR Systems (ASX: EBR)

EBR Systems (ASX: EBR) Slumps to New Lows as Capital Raise Sparks Investor Exit

Jun 6, 2026
Proactive Equities Team

EBR Systems has fallen sharply after a major capital raise sparked dilution concerns. Despite the sell-off, the company continues to expand the commercialisation of its FDA-approved WiSE CRT heart-failure technology, supported by growing implant volumes, clinical studies, and international regulatory progress.

4DMedical (ASX: 4DX)

4DMedical (ASX: 4DX) Pulls Back After Breakout Rally

Jun 26, 2026
Proactive Equities Team

4DMedical slipped to A$4.57 after its breakout rally, as traders took profit near A$5.00. Momentum remains constructive, but holding A$4.25–A$4.50 is crucial while CT expansion, acquisitions and SaaS growth support the broader story.

Proactive Equities

At Proactive Equities, we combine deep market expertise with rigorous analysis to deliver stock recommendations you can trust. Our team of seasoned analysts continuously monitor global markets, economic trends, and company fundamentals to identify high-potential investment and trade opportunities.

Company

Home
Pricing
Contact Us
About Us

Resources

ASX Insights
Investing Basics

Links

Privacy Policy
Terms and Conditions
Product Disclosure Statement

Proactive Equities Pty Ltd (ACN: 687 232 471) is a Corporate Authorised Representative (AFSR No. 001318293) of Australia National Investment Group Pty Ltd (ABN: 40 636 343 630), which holds an Australian Financial Services Licence (AFSL no. 522028). The information on this website is general information only and does not constitute personal financial advice. We have not taken the individual circumstances, financial objectives or needs of any investor into account when preparing this information. Investors should consider their circumstances and the relevant PDS for any investment and obtain professional financial and tax advice before making any investment decision. The information on this website is not a recommendation to make any investment or to adopt any particular investment strategy. You should make your own professional assessment of the suitability of this information, relying on your own inquiries. Investments in securities are subject to investment risk. Investment value may go down as wellas up, and investors may not get back the full amount originally invested. Risks include: the investment objective may not be achieved, share market and other market risk, liquidity risk, and currency risk with international investments. Any past performance shown is not an indication of future performance. Commission and other costs charged by executing broker are not considered when calculating past performance. To the extent permitted by law Proactive Equities Pty Ltd accepts no liability for any errors or omissions in, or loss from reliance on the information in this website.

1...323334...39
Page 33 of 39